Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BHVN

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Investors Business Daily

Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.

Investors Business Daily

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test

Biohaven Pharmaceutical said Thursday its experimental ALS treatment failed in a midstage study, leading BHVN stock to dip slightly.

Investors Business Daily

5 Dividend Growth Stocks Currently on Sale

The stock market has been experiencing wild swings since the beginning of the year on various macroeconomic and geopolitical concerns. In an environment of elevated market volatility, dividend growth stocks are considered attractive investments to ensure a steady income stream and capital appreciation. Thus, it could be wise to invest…

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'

Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Biohaven Pharma Hldgs Q1 Earnings

Recap: Biohaven Pharma Hldgs Q1 Earnings

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement.

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion. Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock. The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals

Biohaven inked a pair of deals Friday to outfit its pipeline with several new drugs, but BHVN stock plummeted on quarterly losses.

Investors Business Daily

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has

People

Christopher Raymond

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play